Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.
|Journal||Antimicrobial Agents and Chemotherapy|
|Publication status||Published - 1 Jan 2019|
- Critical care unit
- Monte Carlo simulation
Luque, S., Hope, W., Campillo, N., Muñoz-Bermúdez, R., Sorli, L., Barceló-Vidal, J., González-Colominas, E., Alvarez-Lerma, F., Masclans, J. R., Montero, M., Horcajada, J. P., & Graua, S. (2019). Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrobial Agents and Chemotherapy, 63, [e00378-19]. https://doi.org/10.1128/AAC.00378-19